Thrombocytopenia was the dose-limiting toxicity (DLT) of TMZ and combined subcutaneous immunotherapy with low-dose IL2, GM-CSF and IFNα, and it was dose- and patient-dependent. This evidence concerns the gene IL2 and Thrombocytopenia.